Food News and Research

RSS

U.S. adults support restrictions on e-cigarettes based on potential risks

According to the makers of electronic cigarettes, they are new devices that allow users to inhale nicotine but not the toxins of tobacco cigarettes. Advocates hail e-cigarettes as a possible quit-smoking aid.

14 Sep 2010

Sorghum bran contains high antioxidant, anti-inflammatory properties: Study

A new University of Georgia study has found that select varieties of sorghum bran have greater antioxidant and anti-inflammatory properties than well-known foods such as blueberries and pomegranates.

14 Sep 2010

$Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report$

Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report

A widely prescribed class of drugs is highly effective in reducing common bone fractures in people with osteoporosis, but an expert panel announced today that these same drugs - when used long term - may be related to unusual but serious fractures of the thigh bone.

14 Sep 2010

$Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL$

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

Cell Therapeutics, Inc. today announced that it intends to appeal the U.S. Food and Drug Administration's previously disclosed decision regarding the pixantrone New Drug Application ("NDA") to treat patients with relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL").

14 Sep 2010

BSD publishes article on technology to improve heat therapy delivery for cancer treatment

BSD Medical Corporation today reported publication of an article on BSD's pioneering development of sophisticated technology to improve the delivery of heat therapy for the treatment of certain cancerous tumors.

14 Sep 2010

Roche granted FDA 510(k) clearance for cobas 8000 modular analyzer series

Roche Diagnostics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the cobas® 8000 modular analyzer series, a Serum Work Area solution designed for diagnostic laboratories with a workload of 3-15 million clinical chemistry / immunochemistry tests per year.

From Roche Sequencing and Life Science 14 Sep 2010

AGTC receives grant to evaluate Phase II Human Clinical Trial for LCA retinal disease

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program). The grant will fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Leber congenital amaurosis (LCA), a genetic retinal disease known to cause blindness at an early age.

14 Sep 2010

Tony Blair's 'Commission for Africa' issues new report: Africa experiences economic growth, donors need to honor commitments

The Commission for Africa, a panel set up by former British Prime Minister Tony Blair, issued a report Monday which says international donors must follow up on aid commitments to Africa and help the continent address new challenges,

14 Sep 2010

African Green Revolution Forum concludes with 'Green Revolution' action plan

Participants at the first meeting of the African Green Revolution Forum (AGRF) - which wrapped up recently in Accra, Ghana - drew up a "Green Revolution" action plan aimed at ensuring food security in Africa, SciDev.Net reports. The forum is the result of a challenge, issued by former U.N. Secretary General Kofi Annan, which calls on the private and public sectors to work together to achieve the Millennium Development Goals.

14 Sep 2010

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for Fluzone® Intradermal (Influenza Virus Vaccine). The file has been accepted by the FDA and an action date is anticipated in the first half of 2011.

From BD (Becton, Dickinson and Company) 14 Sep 2010

Potassium salt intake can improve blood pressure: Study

An increased intake of 'good' potassium salts could contribute significantly to improving blood pressure at the population level. The favourable effect brought about by potassium is even estimated to be comparable with the blood pressure reduction achievable by halving the intake of 'bad' sodium salts (mostly from table salt).

14 Sep 2010

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Pharmacyclics, Inc. today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010.

14 Sep 2010

NUH receives DSRB approval for new comparative study with TIGR Matrix Surgical Mesh

Novus Scientific Pte. Ltd today announced that the National University Hospital (NUH), Singapore has received Domain Specific Review Board (DSRB i.e. IRB equivalent) provisional approval for a new study: Abdominal Wall Closure After Lipectomy, TRAM/DIEP Flap - Comparison of TIGR (100% Resorbable) vs Polypropylene (Permanent) Mesh.

13 Sep 2010

Counterfeit drugs become growing problem

"Last year, nearly 1,700 incidents of counterfeit drugs were reported worldwide, triple the number in 2004, says the Pharmaceutical Security Institute (PSI), a group funded by drugmakers," USA Today reports. "Estimates for the size of the counterfeit drug market range from $75 billion to $200 billion a year. The market is likely much bigger because many cases are hard to detect.

13 Sep 2010

First US implantation of Medtronic Tri-Ad Semi-Flexible Tricuspid Annuloplasty Ring

David H. Adams, MD, Marie-Jos-e and Henry R. Kravis Professor and Chairman of the Department of Cardiothoracic Surgery at The Mount Sinai Medical Center, has performed the first implantation of the Medtronic Tri-Ad Semi-Flexible Tricuspid Annuloplasty Ring in the United States. Dr. Adams invented the ring, which was recently approved by the Food and Drug Administration.

13 Sep 2010

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Sep 2010

FDA updates Shire's ProAmatine medicine for symptomatic orthostatic hypotension treatment

Shire, the global specialty biopharmaceutical company, announces that the United States Food and Drug Administration today posted an update on its website related to ProAmatine (known generically as midodrine), a medicine approved for the treatment of symptomatic orthostatic hypotension.

13 Sep 2010

Forest files response to FDA Complete Response Letter for roflumilast NDA

Forest Laboratories, Inc. today announced that it has filed a response to the U.S. Food & Drug Administration (FDA) addressing topics raised in the complete response letter regarding the New Drug Application (NDA) for roflumilast. Forest licenses roflumilast from Nycomed, which submitted the original NDA.

13 Sep 2010

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase III trial for its JAK1 and JAK2 inhibitor, INCB18424 in patients with polycythemia vera (PV), a blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms (MPNs).

13 Sep 2010

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

XenoPort, Inc. announced today that it plans to move arbaclofen placarbil (AP), also known as XP19986, into Phase 3 development as a potential treatment of spasticity in multiple sclerosis (MS) patients.

13 Sep 2010

Food News and Research

U.S. adults support restrictions on e-cigarettes based on potential risks

Sorghum bran contains high antioxidant, anti-inflammatory properties: Study

Bisphosphonates drug may lead to atypical femur fractures in osteoporosis patients: Report

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

BSD publishes article on technology to improve heat therapy delivery for cancer treatment

Roche granted FDA 510(k) clearance for cobas 8000 modular analyzer series

AGTC receives grant to evaluate Phase II Human Clinical Trial for LCA retinal disease

Tony Blair's 'Commission for Africa' issues new report: Africa experiences economic growth, donors need to honor commitments

African Green Revolution Forum concludes with 'Green Revolution' action plan

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

Potassium salt intake can improve blood pressure: Study

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

NUH receives DSRB approval for new comparative study with TIGR Matrix Surgical Mesh

Counterfeit drugs become growing problem

First US implantation of Medtronic Tri-Ad Semi-Flexible Tricuspid Annuloplasty Ring

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

FDA updates Shire's ProAmatine medicine for symptomatic orthostatic hypotension treatment

Forest files response to FDA Complete Response Letter for roflumilast NDA

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

Understanding cultivated meat and its global potential eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News